Nimodipine

Nimodipine is a second-generation 1,4-dihydropyridine calcium channel blocker. It was initially invented for the management of systemic hypertension. FDA approved the use of nimodipine for the first time in 1988. However, its use is restricted mainly in the management of vasospasm following subarachnoid hemorrhage. It also has numerous off-label uses. This activity outlines the indications, mechanism of action, methods of administration, significant adverse effects, contraindications, monitoring, and toxicity of nimodipine, so providers can direct patient therapy successfully in instances where nimodipine provides a benefit to patient care.
(Copyright © 2022, StatPearls Publishing LLC.)